TMS & Neuromodulation · Part 8

Overview

Transcranial magnetic stimulation (TMS) research now spans neurology, psychiatry, pain medicine, rehabilitation, cognition, and precision neuroscience. That breadth is scientifically exciting—and easy to misrepresent. A positive small trial does not establish routine clinical effectiveness, and an FDA authorization for one device and protocol does not authorize every form of TMS for the same diagnosis.

The most useful way to understand the frontier is to separate three questions:

1. Is there a biological rationale? Can a reachable cortical site influence a relevant network?
2. Is there replicated clinical efficacy? Do well-controlled, adequately sized, preferably multisite trials show meaningful benefit?
3. Is there an established treatment pathway? Are the device, protocol, safety requirements, durability, cost, and regulatory status sufficiently defined for routine care?

The most important points are:

• Neuropathic pain has some of the strongest evidence outside established psychiatric indications. High-frequency motor-cortex rTMS has supportive guideline and multicenter trial data, but no broad U.S. FDA pain indication.¹²
• Cognitive and movement-disorder studies show signals, not established disease-modifying treatment. Alzheimer/MCI and Parkinson studies remain heterogeneous in target, dose, outcomes, and follow-up.³⁴
• PTSD is no longer entirely investigational in the United States. A specific EEG-informed MeRT system became FDA-cleared in June 2026; conventional or differently personalized PTSD protocols remain off-label or investigational.⁵
• Accelerated TMS is partly established, partly frontier. Several complete schedules are now authorized, while one-day, drug-augmented, altered-spacing, or otherwise modified regimens require their own evidence.⁶⁷
• Connectivity targeting has direct randomized support in one accelerated setting. It is promising, but it is not proof that every “MRI-guided” or “precision” service improves outcomes.⁸
• TMS-EEG and closed-loop stimulation are research platforms. Methodological variability still limits routine biomarker-guided decision-making.⁹

Evidence cutoff: This article reflects publicly available evidence and U.S. regulatory information through July 10, 2026. “Investigational” here means that a use, device, target, or schedule lacks an applicable FDA authorization and/or sufficiently mature evidence for routine clinical adoption; it does not mean research is unimportant or that benefit is impossible.

---

Why Early TMS Results Often Need Cautious Interpretation

TMS trials face several methodological challenges:

• Blinding is difficult. Active stimulation clicks, taps the scalp, and contracts muscles; an imperfect sham can create different expectations.
• Protocols vary enormously. Target, coil, frequency, intensity, train structure, total pulses, course duration, and concurrent treatment can all differ.
• Small samples are unstable. A few unusually strong responders can create a large average effect that does not replicate.
• Outcome flexibility matters. A study can measure many scales and time points; the prespecified primary endpoint deserves more weight than a favorable secondary or subgroup result.
• Publication bias favors positive findings. Negative small studies are less likely to appear or attract attention.
• Short-term change may not equal durable function. A statistically significant symptom score at one week may not translate into sustained independence, return to work, fewer medications, or disease modification.

For an investigational use, the question is not merely whether “there are studies.” It is whether independent, rigorous trials converge on the same clinically meaningful result using a reproducible protocol.

Neuropathic Pain: A Leading Neurological Candidate

High-frequency rTMS over the primary motor cortex has one of the stronger evidence bases among non-FDA-authorized neurological applications. The 2020 evidence-based guideline assigned high-level support to selected motor-cortex protocols for neuropathic pain.¹

A four-center randomized double-blind sham-controlled trial followed adults with peripheral neuropathic pain over 25 weeks. Neuronavigated 10-Hz stimulation of the motor cortex, but not a dorsolateral-prefrontal target, produced greater pain relief than sham with a repeated-session schedule.²

Important qualifications remain:

• “Neuropathic pain” includes different causes and body distributions;
• benefit is generally partial rather than curative;
• maintenance schedules and long-term cost are not standardized;
• evidence for fibromyalgia, low-back pain, pelvic pain, complex regional pain, and other chronic pain syndromes is not interchangeable with evidence for confirmed neuropathic pain;
• there is no broad U.S. FDA clearance for rTMS as a chronic-pain treatment.

Status: promising and supported by meaningful evidence for selected neuropathic pain protocols, but still off-label in the United States.

Alzheimer Disease and Mild Cognitive Impairment

Researchers have stimulated prefrontal, parietal, precuneus, and other targets, sometimes pairing TMS with cognitive exercises. Meta-analyses report short-term improvement on some global cognitive measures in mild cognitive impairment (MCI) and Alzheimer disease, including newer 2026 syntheses.³¹⁰

The limitations are substantial:

• small trials and variable diagnostic criteria;
• different targets, pulse patterns, cognitive tasks, and outcome scales;
• short follow-up and incomplete blinding;
• uncertainty about clinically meaningful daily function;
• no evidence that TMS removes amyloid or tau, prevents dementia, or slows neurodegeneration.

A cognitive score improving for weeks is not the same as disease modification. Patients should not delay a standard cognitive evaluation, treatment of reversible contributors, safety planning, or discussion of approved therapies in order to pursue an experimental TMS program.

Status: investigational; possible short-term cognitive signals, no FDA authorization for Alzheimer disease or MCI, and no proven disease-modifying effect.

Parkinson Disease and Other Movement Disorders

Studies in Parkinson disease have targeted primary motor cortex, supplementary motor area, dorsolateral prefrontal cortex, cerebellum, and combinations of regions. A 2026 systematic review and meta-analysis of randomized trials reported pooled improvement in motor and some nonmotor outcomes, while emphasizing inconsistent protocols and the need for larger multicenter trials.⁴

TMS does not replace levodopa, exercise, physical therapy, deep brain stimulation, focused ultrasound, or other established Parkinson treatments. It has not been shown to slow alpha-synuclein pathology or neurodegeneration. Apparent benefits in motor scores can also be influenced by medication timing and short follow-up.

Research is extending to freezing of gait, dystonia, essential tremor, dyskinesia, and cerebellar disorders, but no general U.S. authorization exists for TMS treatment of these movement conditions.

Status: investigational; potentially useful symptomatic signals, substantial heterogeneity, no proven disease modification.

Stroke Rehabilitation

Post-stroke TMS research has used low-frequency stimulation of the contralesional hemisphere, high-frequency stimulation of the affected hemisphere, bilateral protocols, theta burst, and combinations with physical, occupational, speech, or language therapy. Earlier evidence-based guidelines supported certain postacute motor-recovery protocols, but study results vary by stroke location, timing, deficit, target, and rehabilitation intensity.¹

The core scientific challenge is that “stroke recovery” is not one outcome. Arm strength, hand dexterity, aphasia, neglect, swallowing, gait, and spasticity involve different networks. A protocol helpful in a selected subacute motor-recovery population should not be marketed as a general stroke treatment.

Status: investigational in the United States; encouraging evidence for selected protocols, but insufficiently standardized for a broad treatment claim.

Tinnitus

Low-frequency temporal or temporoparietal rTMS has been studied for chronic tinnitus based on models of abnormal auditory-cortex excitability. Meta-analyses have reached mixed conclusions, with variable sham methods, targets, symptom duration, and durability.¹¹¹

A short-lived reduction in tinnitus loudness or distress is not the same as a reliable long-term treatment. Evaluation for hearing loss, medication effects, pulsatile tinnitus, unilateral symptoms, and other otologic or neurological causes remains essential.

Status: investigational; inconsistent evidence and no applicable U.S. FDA authorization.

PTSD After the 2026 MeRT Clearance

PTSD illustrates why regulatory precision matters. In June 2026, the FDA cleared the MeRT system as an adjunct for adult PTSD. The system analyzes resting EEG/ECG and recommends a stimulation frequency from 8 to 13 Hz for dorsomedial-prefrontal treatment with compatible TMS hardware.⁵

This moved one complete PTSD treatment out of the purely investigational category. It did not establish that:

• all prefrontal TMS treats PTSD;
• another EEG-guided system is equivalent;
• frequency personalization itself caused the benefit;
• TMS should replace trauma-focused psychotherapy or medication.

The FDA summary specifically notes that the pivotal 158-participant trial evaluated the MeRT system as a whole and was not designed to isolate the independent value of EEG-selected frequency.⁵ Conventional rTMS, theta-burst, and other targeting approaches for PTSD therefore remain off-label or investigational unless supported by a separate authorization.

Other Psychiatric and Behavioral Conditions

Bipolar Depression

Randomized trials and meta-analyses suggest that certain prefrontal rTMS protocols may reduce bipolar depressive symptoms. However, bipolar depression differs diagnostically and therapeutically from major depressive disorder, and most U.S. MDD device labels do not create a blanket bipolar indication. Mood-stabilizer use, mixed features, psychosis, and treatment-emergent mania require specialist assessment.¹²

Status: off-label/investigational in the United States.

Substance Use Disorders Other Than Smoking

Alcohol, cocaine, methamphetamine, opioid, and cannabis use disorders have been studied with prefrontal, insular-network, and individualized circuit targets. Craving often changes more readily than sustained abstinence, and protocols vary. Smoking cessation remains the established U.S. addiction indication for one specific deep-TMS system.¹³

Status: investigational for substances other than smoking.

Schizophrenia-Spectrum Symptoms

Low-frequency temporoparietal rTMS has been studied for persistent auditory hallucinations, while prefrontal stimulation has been studied for negative symptoms. Some meta-analyses report modest effects, but replication, durability, and protocol standardization remain uncertain.¹

Status: investigational; it should not replace antipsychotic treatment, medical assessment, or urgent care for dangerous psychosis.

Eating Disorders and Other Conditions

Research continues in anorexia nervosa, bulimia nervosa, binge-eating disorder, attention-deficit/hyperactivity disorder, autism-related symptoms, generalized anxiety disorder, panic disorder, functional neurological disorder, fatigue, and many other conditions. The existence of a registered trial or small case series does not establish a routine clinical indication.

Status: investigational unless an exact device and indication have a current FDA authorization.

---

The Protocol Frontier

Accelerated and Ultra-Accelerated Treatment

Accelerated treatment delivers multiple sessions per day. The SAINT/SNT system and the May 2026 MagVenture accelerated platform establish that some complete schedules can meet U.S. regulatory standards.⁶⁷ The remaining frontier includes:

• single-day or two-day courses;
• different intersession intervals;
• higher or lower pulse totals;
• weekend-only or intermittent schedules;
• accelerated treatment for diagnoses other than the authorized indication;
• combining acceleration with unvalidated targeting or dosing algorithms.

Compressing an established six-week course is not merely a scheduling decision. Spacing between sessions may affect plasticity, efficacy, and safety. A clinic should identify the exact evidence and authorization for its schedule.

Connectivity- and Circuit-Guided Targeting

TMS directly stimulates accessible cortex but can influence connected deeper networks. This has led researchers to select cortical targets based on functional connectivity to symptom-relevant circuits rather than solely on scalp measurements.

In a 2026 randomized trial of 40 adults receiving the same high-dose accelerated TMS course, individualized connectivity-based targeting produced a larger median reduction in depression severity at one month than Beam F3 scalp targeting.⁸ This is important direct evidence, but the study was designed to estimate effect size rather than serve as a definitive multisite efficacy trial.

“MRI-guided” can mean several different things:

• structural-MRI neuronavigation: more reproducible anatomical placement;
• electric-field modeling: estimating field strength and orientation in individual anatomy;
• functional-connectivity targeting: selecting a site based on network relationships;
• group-average coordinates: using a target derived from prior imaging rather than the patient’s own connectivity.

These are not interchangeable, and each claim should be stated precisely.

Electric-Field-Informed Dosing

Motor-threshold dosing does not guarantee the same prefrontal electric field across patients because anatomy and scalp-to-cortex distance differ. Computational models may help estimate the field at the treatment target and adjust coil orientation or intensity. The challenge is that an anatomically equal field is not necessarily a biologically equal dose, and clinical outcome thresholds have not been standardized.¹⁴

Status: promising personalization research; some systems display patient-specific field estimates, but outcome-guided dosing remains under development.

TMS-EEG, Biomarkers, and Closed-Loop Stimulation

TMS combined with electroencephalography can record how a pulse propagates through cortical networks. Researchers are studying whether these responses can diagnose circuit dysfunction, predict treatment benefit, or determine when and where to stimulate.⁹

Clinical translation remains difficult because muscle and sensory artifacts can dominate the signal, and laboratories differ in hardware, preprocessing, reference choices, timing, and outcome definitions. A 2026 integrative review concluded that methodological fragmentation still limits routine biomarker use.⁹

Closed-loop systems aim to deliver stimulation at a particular phase or state of ongoing brain activity. This is conceptually attractive, but most psychiatric and neurological applications remain research tools. The MeRT PTSD authorization is algorithm-guided frequency selection from resting EEG; it is not the same as real-time, pulse-by-pulse closed-loop stimulation.⁵

Combining TMS With Learning, Psychotherapy, or Medication

Neural state can influence stimulation effects. Researchers are pairing TMS with exposure therapy, cognitive training, motor rehabilitation, psychotherapy, sleep interventions, and medications intended to enhance plasticity. OCD symptom provocation is already part of one authorized protocol, showing that “what the brain is doing during treatment” can be clinically relevant.¹⁵

For most combinations, the best task, timing, medication, and target are unknown. A positive combined-treatment study cannot determine whether TMS, the accompanying therapy, or their interaction caused the result unless the trial is designed to separate those effects.

Robotic and Remote Delivery

Robotic coil holders, automated tracking, and adaptive positioning may improve reproducibility and reduce staff burden. Portable single-pulse TMS is already authorized for migraine, but repetitive home TMS for psychiatric or neurological treatment raises additional questions about positioning, supervision, seizure response, dosing control, adherence, and cybersecurity.¹⁶

Status: robotic positioning is emerging; unsupervised home repetitive TMS remains investigational unless a specific system receives an applicable authorization.

How to Evaluate an Investigational TMS Claim

When Off-Label Treatment May Be Reasonable

Off-label device use is not automatically inappropriate. Medicine sometimes advances before a label changes. A defensible off-label TMS decision should include:

• a clear diagnosis and clinically important unmet need;
• a plausible target and protocol supported by more than anecdote;
• transparent discussion of evidence quality and regulatory status;
• reasonable alternatives and the consequences of delaying them;
• appropriate safety screening and trained supervision;
• defined symptom and functional outcomes;
• a stopping rule if benefit does not emerge;
• no misleading billing or guarantee of insurance reimbursement.

Clinical-trial participation is often the best route when the intervention is highly experimental.

The Most Promising Direction Is Better Questions, Not More Hype

The future of TMS will likely involve more than adding diagnoses to a list. The deeper opportunity is to learn:

• which circuit is causally related to a patient’s symptom;
• which accessible cortical point best reaches that circuit;
• what electric-field dose and neural state produce useful plasticity;
• how to know early whether the target is being engaged;
• how to preserve benefit with the least treatment burden.

Bottom line: the TMS frontier is real, but it is uneven. Motor-cortex rTMS for selected neuropathic pain has notable evidence; cognitive, Parkinson, stroke, tinnitus, and many psychiatric applications remain investigational; and adult PTSD now has one specific authorized EEG-informed pathway. Accelerated schedules, connectivity targeting, electric-field modeling, TMS-EEG, and closed-loop methods may make treatment more precise. Their value should be judged by replicated clinical outcomes—not by the sophistication of the imaging, the novelty of the algorithm, or the confidence of the marketing.

Previous: Beyond Depression: Other FDA-Authorized Uses of TMS

---

References

1. Lefaucheur JP, Aleman A, Baeken C, et al. Evidence-based guidelines on the therapeutic use of repetitive transcranial magnetic stimulation: an update (2014-2018). Clin Neurophysiol. 2020;131(2):474-528. doi:10.1016/j.clinph.2019.11.002.
2. Attal N, Poindessous-Jazat F, De Chauvigny E, et al. Repetitive transcranial magnetic stimulation for neuropathic pain: a randomized multicentre sham-controlled trial. Brain. 2021;144(11):3328-3339. doi:10.1093/brain/awab208.
3. Wen J, Li M, Xu J, et al. A meta-analysis of the effect of non-invasive neuromodulation techniques on improving cognitive function in patients with Alzheimer’s disease. Neurol Sci. 2026. doi:10.1007/s10072-026-08852-5.
4. Lu W, Yan L, Li C, Wang K, Wang Q, Xu S, Wang B. Efficacy and safety of repetitive transcranial magnetic stimulation on motor function, depression, and cognitive dysfunction in Parkinson’s disease: a systematic review and meta-analysis of randomized controlled trials. Clin Park Relat Disord. 2026;14:100422. doi:10.1016/j.prdoa.2026.100422.
5. U.S. Food and Drug Administration. MeRT System for adjunctive treatment of adult PTSD: 510(k) Summary (K260402). June 3, 2026.
6. U.S. Food and Drug Administration. Magnus Neuromodulation System with SAINT Technology: 510(k) Summary (K220177). September 1, 2022.
7. U.S. Food and Drug Administration. MagVenture Accelerated TMS Therapy System: 510(k) Summary (K260189). May 22, 2026.
8. Taylor JJ, Kare MR, Haj-Darwish D, et al. Connectivity- vs scalp-based targeting of accelerated transcranial magnetic stimulation for depression: a randomized clinical trial. JAMA Psychiatry. Published online June 24, 2026. doi:10.1001/jamapsychiatry.2026.1100.
9. Wang W, He Y, Xing H, Zhang H. Toward clinical translation of TMS-EEG: an integrative review of multidimensional neurophysiological measures. Front Hum Neurosci. 2026;20:1804482. doi:10.3389/fnhum.2026.1804482.
10. Lin Y, Tao Y, He Z, Wang H, Zheng Y, Jin Y. Efficacy of transcranial magnetic stimulation for mild cognitive impairment: a systematic review and meta-analysis of randomized controlled trials. Front Neurol. 2026;17:1788223. doi:10.3389/fneur.2026.1788223.
11. Liang Z, et al. Repetitive transcranial magnetic stimulation on chronic tinnitus: a systematic review and meta-analysis. BMC Psychiatry. 2020;20:547.
12. Nguyen TD, Hieronymus F, Lorentzen R, McGirr A, Østergaard SD. The efficacy of repetitive transcranial magnetic stimulation in bipolar depression: a systematic review and meta-analysis. J Affect Disord. 2021;279:250-255. doi:10.1016/j.jad.2020.10.013.
13. Zangen A, Moshe H, Martinez D, et al. Repetitive transcranial magnetic stimulation for smoking cessation: a pivotal multicenter double-blind randomized controlled trial. World Psychiatry. 2021;20(3):397-404.
14. Peterchev AV, Wagner TA, Miranda PC, et al. Fundamentals of transcranial electric and magnetic stimulation dose: definition, selection, and reporting practices. Brain Stimul. 2012;5(4):435-453.
15. Carmi L, Tendler A, Bystritsky A, et al. Efficacy and safety of deep transcranial magnetic stimulation for obsessive-compulsive disorder. Am J Psychiatry. 2019;176(11):931-938.
16. U.S. Food and Drug Administration. SAVI Dual Migraine Therapy: portable single-pulse TMS for acute and prophylactic migraine treatment (K230358). May 16, 2023.

Medical disclaimer. This article is provided for general educational and informational purposes only. It does not constitute individualized medical advice, diagnosis, treatment, a recommendation for any specific test or therapy, or informed consent. Medical information changes over time, and this article may not reflect developments occurring after its stated review date or apply to your individual circumstances. Do not disregard or delay professional medical advice, or start, stop, or change any medication or treatment, based on this article. Discuss personal medical decisions with a qualified healthcare professional who can evaluate your individual history and circumstances. Accessing or using this website does not, by itself, create a physician–patient relationship with Los Altos Neurology or any of its clinicians. Do not use this website for urgent or emergency medical concerns; call 911 or seek immediate emergency care. Although Los Altos Neurology makes reasonable efforts to provide accurate and current information, it does not guarantee that all content is complete, current, or applicable to every individual. See our full Medical Disclaimer.